Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)
Updated: December 20, 2025 Gilead Sciences, Inc. (NASDAQ: GILD) heads into the weekend with fresh policy headlines, a high-profile pricing agreement tied to the Trump administration’s TrumpRx initiative, and renewed attention on the company’s next-generation HIV portfolio. The combination has kept Gilead stock near the top of its recent trading range—while also reopening the debate investors have wrestled with all year: how much upside can the pipeline deliver, and how much risk does U.S. pricing policy introduce? Below is a comprehensive look at what’s driving Gilead shares as of 20.12.2025, what analysts are forecasting next, and the key catalysts (and